

REMARKS

Claims 1-31 are pending in the above-identified application. The Examiner has required an election of a single disclosed species under 35 U.S.C. § 121 to one of the following 18 proteins as targets for the immunoglobulin molecules recited in the claims.

1. SP-10
2. MSA-63
3. LDH-C4
4. Gonadotropin releasing hormone
5. Gonadotropin
6. Prostaglandin F₂ α
7. Oxytocin
8. Gonadotropin receptors
9. SP-17
10. PH-20
11. FA-1
12. FA-2
13. PH-30
14. RSA
15. HAS-63
16. ZP1
17. ZP2
18. ZP3


Without admitting that the species identified by the Examiner are patentably distinct and in order to be fully responsive, Applicants hereby elect the species related to Gonadotropin releasing hormone, for prosecution on the merits, and without prejudice to Applicants' right to pursue the non-elected subject matter in related applications if a generic claim is not found allowable in the present application. It is believed that claims 1, 4, 5, 7-11, 14, 15, 17-22, 25, 26, 28-31 read on the elected species. Applicants believe that claims 1, 5, 7-11, 15, 17-22, 26, 28-31 are generic. Once the claims directed to the species elected are deemed allowable, Applicants will be entitled to consideration of patentability of the breadth of the generic claims and additional species encompassed by the generic claims (M.P.E.P. § 809.02 (a)).

CONCLUSION

Entry of the remarks made herein is respectfully requested. The Examiner is invited to contact the undersigned with any questions concerning the foregoing.

Respectfully submitted,

Date: October 30, 2003

 40,922
Margaret B. Brivanlou (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036
(212) 790-9090